Evidence map›Paper›PMID 30709415›Full record

ArticleInfectious diseases of poverty2019

Effect of financial support on reducing the incidence of catastrophic costs among tuberculosis-affected households in Indonesia: eight simulated scenarios.

Ahmad Fuady, Tanja A J Houweling, Muchtaruddin Mansyur, Erlina Burhan, Jan Hendrik Richardus

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. COVID-19 and Tuberculosis-Related Catastrophic Costs.The American journal of tropical medicine and hygiene · 2020
    Article
  18. Article
  19. Catastrophic costs due to tuberculosis worsen treatment outcomes: a prospective cohort study in Indonesia.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ahmad FuadyDepartment of Public Health, Erasmus MC, University Medical Centre Rotterdam, P.O. Box 2040, 3000CA, Rotterdam, the Netherlands. a.fuady@erasmusmc.nl.ORCID http://orcid.org/0000-0003-0030-0524
Tanja A J HouwelingDepartment of Public Health, Erasmus MC, University Medical Centre Rotterdam, P.O. Box 2040, 3000CA, Rotterdam, the Netherlands.
Muchtaruddin MansyurDepartment of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Erlina BurhanDepartment of Respiratory and Pulmonology, Persahabatan Hospital - Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Jan Hendrik RichardusDepartment of Public Health, Erasmus MC, University Medical Centre Rotterdam, P.O. Box 2040, 3000CA, Rotterdam, the Netherlands.

Funding

Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan, LPDP) 20160122045299
6 · The paper itself

Abstract

backgroundThe World Health Organization's End Tuberculosis Strategy states that no tuberculosis (TB)-affected households should endure catastrophic costs due to TB. To achieve this target, it is essential to provide adequate social protection. As only a few studies in many countries have evaluated social-protection programs to determine whether the target is being reached, we assessed the effect of financial support on reducing the incidence of catastrophic costs due to TB in Indonesia.

methodsFrom July to September 2016, we interviewed adult patients receiving treatment for TB in 19 primary health centres in urban, sub-urban and rural area of Indonesia, and those receiving multidrug-resistant (MDR) TB treatment in an Indonesian national referral hospital. Based on the needs assessment, we developed eight scenarios for financial support. We assessed the effect of each simulated scenario by measuring reductions in the incidence of catastrophic costs.

resultsWe analysed data of 282 TB and 64 MDR-TB patients. The incidences of catastrophic costs in affected households were 36 and 83%, respectively. Patients' primary needs for social protection were financial support to cover costs related to income loss, transportation, and food supplements. The optimum scenario, in which financial support would be provided for these three items, would reduce the respective incidences of catastrophic costs in TB and MDR-TB-affected households to 11 and 23%. The patients experiencing catastrophic costs in this scenario would, however, have to pay high remaining costs (median of USD 910; [interquartile range (IQR) 662] in the TB group, and USD 2613; [IQR 3442] in the MDR-TB group).

conclusionsIndonesia's current level of social protection is not sufficient to mitigate the socioeconomic impact of TB. Financial support for income loss, transportation costs, and food-supplement costs will substantially reduce the incidence of catastrophic costs, but financial support alone will not be sufficient to achieve the target of 0% TB-affected households facing catastrophic costs. This would require innovative social-protection policies and higher levels of domestic and external funding.

Indexed as

Financial SupportAdolescentAdultAgedFamily CharacteristicsHealth Care CostsHumansIndonesiaMiddle AgedModels, EconomicTuberculosisTuberculosis, Multidrug-ResistantYoung AdultCash transferCatastrophic costFinancial supportIndonesiaMultidrug-resistant tuberculosisSocial protectionTuberculosis

Identifiers

PMID30709415
PMCPMC6359783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.